Abstract: BACKGROUND: Live vaccines are generally contraindicated on immunosuppressive therapy due to safety concerns. However, data are limited to corroborate this practice. OBJECTIVES: To estimate the safety of live vaccinations in patients with immune-mediated inflammatory diseases (IMID) or solid organ transplantation (SOT) on immunosuppressive treatment and in patients after bone-marrow transplantation (BMT). DATA SOURCES: A search was conducted in electronic databases (Cochrane, Pubmed, Embase) and additional literature was identified by targeted searches. ELIGIBILITY CRITE-RIA: Randomized trials, observational studies and case reports. POPULATION: Patients with IMID or SOT on immunosuppressive treatment and BMT patients <2years after transplantation. INTERVEN-TION/VACCINATIONS LOOKED AT Live vaccinations: mumps, measles, rubella (MMR), yellow fever (YF), varicella vaccine (VV), herpes zoster (HZ), oral typhoid, oral polio, rotavirus, Bacillus CalmetteGuérin (BCG), smallpox. DATA EXTRACTION: One author performed the data extraction using predefined data fields. It was cross-checked by two other authors. RESULTS: 7305 articles were identified and 64 articles were included: 40 on IMID, 16 on SOT and 8 on BMT patients. In most studies, the administration of live vaccines was safe. However, some serious vaccine-related adverse events occurred. 32 participants developed an infection with the vaccine strain; in most cases the infection was mild. However, in two patients fatal infections were reported: a patient with RA/SLE overlap who started MTX/dexamethasone treatment four days after the YFV developed a yellow fever vaccine-associated viscerotropic disease (YEL-AVD) and died. The particular vaccine lot was found to be associated with a more than 20 times risk of YEL-AVD. One infant whose mother was under infliximab treatment during pregnancy received the BCG vaccine at the age of three months and developed disseminated BCG infection and died. An immunogenicity assessment was performed in 43 studies. In most cases the patients developed satisfactory seroprotection rates. In the IMID group, YFV and VV demonstrated high seroconversion rates. MTX and tumor necrosis factor inhibitory therapy appeared to reduce immune responses to VV and HZ vaccine, but not to MMR and YF-revaccination. Seroconversion in SOT and BMT patients showed mostly higher rates for rubella than for measles, mumps and varicella. LIMITATIONS: Risk of bias was high in the majority of studies since 39 of them were observational and 17 were case series/case reports. Only eight studies were randomized trials. BMT patient numbers included in this review were low. CONCLUSIONS: Although live vaccinations were safe and sufficiently immunogenic in most studies, some serious reactions and vaccine-related infections were reported in immunosuppressed IMID and SOT patients. Apart from mild vaccine-related infections MMR and VV vaccines were safe when administered less than two years after BMT. IMPLICATIONS OF KEY FINDINGS: Until further data are available, live vaccinations under most immunosuppressive treatments should only be administered after a careful risk benefit assessment of medications and dosages. FUNDING: None. 
Immunizations are an important means for preventing infectious diseases in healthy individuals and 3 especially in vulnerable patient groups with immunocompromising conditions. However, live 4 vaccinations contain an attenuated vaccine strain, which has the theoretical potential to revert to the 5 original pathogenic form and to induce infection by the vaccine strain, particularly in 6 immunocompromised individuals. Serious infections with the vaccine strain and even deaths have 7 occurred in HIV patients, leukemia patients and patients with inherited immunodeficiencies [1] [2] [3] [4] . 8
The number of individuals treated with immunosuppressive medications due to immune-mediated 9 inflammatory diseases (IMID), solid organ transplantation (SOT) or patients after bone-marrow 10 transplantation (BMT) has grown over the last decades [5] . Clinicians are increasingly exposed to the 11 dilemma on whether an immunosuppressed patient can receive a live vaccine -which is very 12 important as severe infections with infections preventable by live vaccinations such as measles and 13 varicella can occur on immunosuppressive therapy [6, 7] . On the other hand, the live vaccine itself 14 may impose a danger to the immunosuppressed individual. Furthermore, vaccines may be less 15 effective when administered to an impaired immune system [8] . 16 To date, live vaccines are contraindicated under most immunosuppressive therapies. However, data 17 are generally scarce. Over the last few years efforts have been made to evaluate the safety of some 18 live vaccines in selected immunosuppressed individuals by conducting both, retrospective and 19 prospective studies. Further data have become available as live vaccines were occasionally 20 administered inadvertently or after a careful risk-benefit assessment to individual patients. 21
In this systematic review, we aim to provide an overview on the results of published randomized 22 trials, observational studies and case reports on live vaccinations in patients with IMIDs or SOT on 23 immunosuppressive therapy as well as BMT patients who received a live vaccine less than two years 24 after receiving the BMT. Live vaccines are generally accepted after this 2 year time period in BMT 25 patients if no immunosuppressive therapy is given and no GvHD is present [9] . Our primary objective 1 is to examine the safety of the live vaccinations (mumps, measles, rubella (MMR), yellow fever (YF), 2 varicella vaccine (VV), herpes zoster (HZ), oral typhoid, oral polio, rotavirus, Bacillus Calmette-Guérin 3 (BCG), smallpox) in patients on immunosuppressive treatment with an IMID or SOT as well as 4 patients less than two years after BMT. This includes the assessment (i) of systemic or local vaccine 5 reactions (ii) of the risk of infection with the attenuated vaccine strain, and (iii) on whether live 6 vaccinations are associated with relapses/worsening of the underlying disease or organ rejection. 7
Our secondary objectives are to examine the immunogenicity and the clinical protection of live 8 vaccinations in these patients. 9 10 11
Methods 1
Eligibility criteria for study inclusion 2 Population: Patients of any age with an IMID or SOT who were on immunosuppressive treatment at 3 the time of vaccination as well as patients less than two years after BMT were considered. As live 4 vaccines are generally accepted two years after BMT if no immunosuppressive therapy is given and 5
no GvHD is present publications on live vaccines more than two years after BMT were not 6 considered. Search terms were peer reviewed during the development process. The search terms in Figure 1  6 were used in combination to search the databases. Corresponding Medical Subject Headings and 7
Embase subject headings were searched for. 8
Study selection 9
Two review authors performed eligibility assessment based on titles, key words, and abstracts 10 independently (SB and VKJ). Disagreements between review authors were resolved by consensus. 11
One review author conducted the eligibility assessment (EC) based on the full article; this was 12 checked by two other review authors (SB and VKJ). If authors published several studies on the same 13 subject (e.g. varicella vaccination in stem cell transplantation) we compared sample sizes, outcomes 14 and time frames of study conduct to avoid double counting. 15
Data collection process 16
A data extraction sheet was piloted on five randomly-selected studies and was refined accordingly. 17
Data extraction was performed by one author (EC) and checked by two other authors (SB and VKJ). In 18 case of disagreement, a consensus was sought by discussion between the three authors. In 10 cases, 19 study authors were contacted to receive further/clarifying information. Seven authors answered and 20 in six cases the relevant information could be retrieved. In three cases the author did not respond 21 and it could not be clarified whether the patients were treated with immunosuppressive therapy 22 during the immunization. These three articles were excluded. 23
Data items 24
Information from each record was extracted on year of publication, year of study conduct, country, 1 study design, number of participants, enrolment of controls, number of vaccine doses, underlying 2 disease, immunosuppressive medication, primary vaccine dose or secondary/revaccination vaccine 3 doses, vaccine reaction (local or systemic), infection through vaccine strain, flare of underlying 4 disease (IMID) or transplant rejection (SOT/BMT), immunogenicity assessment performed, test for 5 immunogenicity assessment, time point for immunogenicity assessment, results of immunogenicity 6 assessment, clinical protection assessment performed, duration of follow-up for clinical protection, 7 results of clinical protection assessment, conclusion (see supplementary file). If a live vaccine was 8 administered to a seronegative patient it was defined as a "primary vaccination". If a second 9 vaccination was given or if patients were known to be seropositive at the time of vaccination, the 10 vaccination was defined as "secondary vaccination" or "re-immunization". 11 12 13
Results

1
Study selection 2 7,290 articles were identified through database searching and 15 articles were identified through 3 other sources. After removal of duplicates, 7,187 articles remained. 550 articles were left after title 4 and keyword screening and 105 (IMID n=64, BMT n=20, SOT n=21) articles were left after abstract 5 screening (Figure 2) . The full-text of these articles were assessed for eligibility and finally 64 articles 6 were included in this systematic review (see supplementary file for details on included studies). 7
Of these, 40 (YF n=9 (n=8 in adults, n=1 in children and adults), MMR n=6 (n=1 in adults, n=5 in 8 children), varicella n=12 (n=3 in adults, n=9 in children, n=1 in children and adults), HZ n=8 (all in 9 adults), polio n=1 (adult), BCG n=4 (n=2 in adults, n=2 in children), live typhoid n=1 (adult), smallpox 10 n=1 (adult)) were conducted in IMID patients. 16 studies (YF n=2 (n=1 in adults, n=1 in children and 11 adults), MMR n=7 (all in children), varicella n=11 (n=2 in adults, n=9 in children), BCG n=1 (children)) 12
were identified in SOT patients and eight (MMR n=4 (n=2 in children, n=2 in children and adults), 13 varicella n=5 (n=1 in adults, n=2 in children, n=2 in children and adults)) in BMT patients. Some 14 studies evaluated several live vaccines. No study on rotavirus vaccination was identified. In one study 15 the participants (IMID patients) were vaccinated simultaneously against YF, MMR and varicella. In 16 five studies (SOT patients) the participants were vaccinated against MMR and varicella 17 simultaneously. 41 full-text articles were excluded because patients were not on immunosuppressive 18 therapy at time point of vaccination (IMID or SOT, n=15), administration of live vaccine later than two 19 years after BMT (n=11), no original work (n=12), the results were already presented in other articles 20 (n=2), or because of an additional inherited immunodeficiency of the vaccinated patient (n=1). Out of 21 the 64 included articles, eight were randomized controlled trials (RCTs), 39 observational studies and 22 17 case series/reports. RCTs were only identified in the IMID group (varicella n=5, HZ n=1, YF n=1, 23
MMR n=1). 24
Study characteristics 25
A total of 21,082 patients received a live vaccine in the studies, which were published between 1977 1 and 2016. Studies were conducted in 18 different countries including USA (n=18), Brazil (n=13), Japan 2 (n=6) and Germany (n=4). As some patients received several live vaccines concomitantly the 3 presented numbers may not add up. 4
Immune mediated inflammatory diseases 5
Most of the patients (n=20,556) had an IMID. Of these, 19,630 patients received an HZ, 474 an MMR, 6 233 a YF, 202 a varicella, 10 an oral typhoid, 5 a BCG, one a live poliomyelitis and one a smallpox 7 vaccination. 8
The most frequently represented disease categories in the IMID group are summarized in Table 1 . 9
The participants in the IMID group were under 22 different immunosuppressive medications. The 10 most common medication in this group was glucocorticoids (n=384) with a prednisone-equivalent 11 dosage range of 2.5-35mg/day, followed by methotrexate (MTX, n=268) with a dosage range of 5-12 27mg/m2/week. 98 patients in the IMID group were treated with a combination therapy; 218 13 received a monotherapy with a biological, 39 received a combination therapy with a biological. 633 14 patients received herpes zoster vaccine (HZV) under biological therapy. It was unclear whether this 15 was a mono-or a combination therapy. In this study the medication was only reported in 16 7,780/18,683 patients. So numbers of patients with HZV on immunosuppressive therapy may have 17 been higher [10] . In the IMID group, in 18 studies primary vaccinations were administered, in 13 18 studies secondary doses were given. In six studies a primary and a secondary vaccination were 19 administered and in three studies it was unknown whether a primary or a secondary vaccination was 20
given. Of the 339 SOTs, 271 were liver transplants, 62 kidney transplants, four heart transplants, one small 1 bowel transplant, and one liver and small bowel transplant. The SOT patients were treated with eight 2 different immunosuppressive medications. The most frequently used medication was tacrolimus 3 (TAC, n=134, 2.4-10ng/ml in serum), followed by cyclosporine A (CSA, n=56) with a dosage range 4 from 30-120ug/l; 70 transplanted participants were under a combination therapy. In seven studies 5 patients received a primary vaccination, in one study only revaccinations were given and in eight 6 studies the patients received a primary vaccination as well as a secondary vaccination. 7
BMT 8
Only a small part of the participants were patients with BMT (n=187). Of these, 152 received an 9 MMR vaccination and 38 received a VV. The underlying diseases of BMT patients are specified in 10 Table 2 . All BMT patients (n=38) who received VV, were not on current immunosuppressive therapy. 11 27 patients who received an MMR immunization were treated with an immunosuppressive therapy 12 at vaccination (CSA n=12, CSA/prednisone n=11; prednisone n=2, mycophenolate-mofetil (MMF) 13 n=2). In one study, seven BMT patients (MMR vaccination n=7, VV n=3) took a calcineurin inhibitor 14 and MMF as graft versus host disease (GvHD) prophylaxis [11] . In five studies only primary 15 vaccinations were administered and in three studies the patients received a primary and a secondary 16 immunization. 17
Results of individual studies 18
Safety 19
Local or systemic vaccine reactions 20
Out of the 21,082 involved participants, local or systemic vaccine-associated adverse reactions were 21 observed in 280 patients (1.3%): 207/20,556 (1.0%) in the IMID group, 61/339 (18.0%) in the SOT 22 group and 12/187 in the BMT group (6.4%). Most frequent adverse reactions (n=269) were mild such 23 as injection-site pain, headache, fatigue, myalgia, fever, arthralgia, and nausea. Serious adverse 24 events (SAEs) were reported by 11 participants (Table 3) . 1
In one study SAEs were reported in 11 IMID patients under prednisone treatment who received HZV 2
[12]. However, SAEs in the placebo group were as frequent as in the HZ-vaccinated group (6.6% vs. 3 5.7%). One of the SAEs in the HZ group was vaccine-related but the exact reason was not mentioned. 4
Six deaths occurred (three in placebo group and three in HZ group), of which none was judged to be 5 vaccine-related. The most frequently reported SAEs were respiratory, thoracic and mediastinal 6 disorders [12]. 7
After receiving MMR, poliomyelitis, small pox, live typhoid and BCG vaccination in the IMID group, 8 there were no reported SAEs. Similarly, in the SOT and BMT group no SAEs were reported. Across 9 IMID, SOT and BMT patients, 17 articles did not document whether adverse events were observed. In the BMT group one patient developed HZ seven days after receiving the varicella vaccine (Table 3) In a self-controlled case-series study, a 12.8 times (95%CI 4.28-38.13, p<0.001) higher exacerbation 5 rate was reported in multiple sclerosis (MS) patients who received YFV under glatiramer acetate and 6 interferon treatment compared to time periods when these patients had not received YFV ("not-at-7 risk-periods") [29] . In a retrospective cohort study by Heijstek et al [30] , no aggravation of disease 8 was registered in the MMR vaccinated JIA patients. In another study by Heijstek and colleagues [31] , 9 the mean number of flares per patient did also not differ significantly between the vaccinated 10 patients and the control group. A boy with atopic dermatitis experienced an exacerbation of the skin 11 disease one week after BCG vaccination [32] . The exacerbation of the skin lesions resolved 3.5 12 months later after treatment. While 1/10 patients with inflammatory bowel disease (IBD) under 13 prednisolone 10mg had a flare 15 days after live typhoid immunization, 8/10 patients reported 14 improvement of abdominal symptoms after 90 days [33] . In three further studies improvement of 15 the basic diseases were reported. Two randomized controlled studies mentioned a significant 16 improvement of the psoriatic area in 83% of psoriasis patients after four doses of VV [34, 35] . Less 17 patients in the control group showed a significant improvement. In a case report, two SLE patients 18 experienced improvement of their extrarenal manifestations after BCG vaccination [36] . 19
SOT 20
In the SOT group, three cases of organ rejections were reported. One patient developed an episode 21 of acute rejection three weeks after measles vaccination. The other patient showed chronic rejection 22 at the time of vaccination and remained unchanged for one year [37] . Another single rejection 23 episode of the liver was reported, which occurred more than one year after a VV and was considered 24 as unassociated to immunization [38] . 25
BMT 1
One child after autologous BMT had a relapse of her malignancy after MMR immunization, the time 2 point was unknown [39] . 3
Immunogenicity 4
In 43 studies an immunogenicity assessment was performed: 23 (YF n=6, MMR n=3, VV n=9, HZ n=5) 5 in the IMID group, 12 (YF n=1, MMR n=7, VV n=4) in the SOT group and in all eight studies (MMR n=3, 6 VV n=5) in the BMT group. In the majority, an immunogenicity assessment was performed before 7 vaccination; the time points for the immunogenicity assessment varied from 15 days to 13 years after 8 vaccination. 9
10
IMID 11
In 19 articles the humoral immune response and in two articles the humoral and cellular response 12 was assessed. In two articles the test method was not documented. In four studies an immunogenicity assessment was performed by humoral tests, in one study by 26 cellular tests and in one study by humoral and cellular tests. In two BMT studies the test was 1
unspecified. 2
Three studies with patients who received an MMR immunization within 24 months after BMT 3 showed a higher seroconversion rate for rubella (86-100%) than for measles (33-46%) and mumps 4 (29-80%) [11, 39, 64] . It was observed that children seroconverted more frequently to measles if they 5 were immunized more than 15 months after BMT (35% prior to versus 78% after 15 months) [64] . 6 Seroconversion rates were 86% for rubella, 43% for measles and 29% for mumps in patients treated 7
with calcineurin inhibitors and MMF after a primary MMR vaccine [11] . 8
In another study, after a primary measles vaccine dose, all patients seroconverted and 78% remained 9 seropositive for at least 12 months [65] . However, only 44% of these patients were on 10 immunosuppressive drugs at the time of vaccination. 11
For varicella vaccination after BMT, seroconversion rates varied between 33 and 89% after a primary 12 VV [11,27,66,67]. In the study in which only 33% seroconversion was achieved, patients were under 13 GvHD-prophylaxis with calcineurin inhibitors and MMF. In the other studies patients were without 14 immunosuppressive treatment. Whether live vaccines can be administered to immunocompromised patients is an often-2 encountered problem by physicians caring for this specific patient group. On the one hand these 3 patients are especially vulnerable from infections (many of them vaccine-preventable) on the other 4 hand there is a potential risk of harming the patient by the administration of a vaccine containing an 5 attenuated vaccine strain, which has the theoretical potential to revert to the original pathogenic 6 form and to induce infection in the immunocompromised individual. Apart from infecting the 7 immunocompromised person, more vaccine-related side effects as well as re-activation of the 8 underlying disease is feared. Therefore this review summarizes available information in order to 9 inform the practitioner of currently available evidence by reviewing and giving an overview on 10 currently available literature on this topic. 11
Generally local and systemic reactions were mild. While they were rare in IMID patients (prevalence 12 of 1%), they occurred more frequently in BMT (6%) and SOT patients (18%). The percentages of 13 adverse events (AEs) appear low compared to AEs reported in the general population [68] [69] [70] [71] . This is 14 most likely due to underreporting of AEs in our included studies. 15
Altogether, 11 SAEs due to local or systemic reactions including three deaths were reported; 16 however, none of the deaths was vaccine-associated. All reported SAEs occurred in IMID patients 17 after HZV. In the other vaccination groups, numbers of patients were low, thus SAEs may not have 18 been observed due to the limited sample sizes. Also in the literature local or systemic SAEs after live 19 vaccinations are extremely rare. For examples, anaphylactic reactions after YFV occur in 0.8-20
1.8/100,000 administered doses and thrombocytopenia after MMR vaccination is estimated to occur 21 in one out of 30,000-40,000 administered MMR doses [72, 73] . Infections through vaccine strains were extremely rare. However, two of them were deadly. One 8 occurred in a patient with RA/SLE overlap who received YFV four days prior to commencement of 9 MTX/dexamethasone treatment. However, the administered vaccine lot was associated with a 20 10 times higher risk of YEL-AVD compared to other YFV lots. A fatal disseminated BCG infection was 11 reported upon vaccination of a three-month-old infant born to a mother under IFX treatment. Thus, 12
infants born to immunosuppressed mothers should be vaccinated with caution. The other vaccine-13 associated infections were either self-limiting or resolved upon treatment. 14 Regarding reactivation of the underlying disease, apart from one article, no increase of flares of 15 underlying autoimmune conditions was encountered. One study detected a more than 12 times 16 elevated risk of MS exacerbation after YFV [29] . However, this self-controlled case series study was 17 criticized for methodological issues [75] . 18
In SOT patients, one liver transplant rejection was reported three weeks after measles vaccination 19 [37] . Acute organ rejections can occur in around 15-25% of liver transplant recipients [76] [77] [78] . Thus it 20
is not surprising to see an acute organ rejection three weeks after measles vaccination (one of 271 21 liver transplant patients who received a live vaccine), which is most likely only timely but not causally 22 associated to vaccination. Details such as numbers on non-serious specific systemic and local 23 reactions were often not presented in the publications. 24 could be identified and all were conducted in IMID patients. However, patient groups, medications, 6 medication dosages and live vaccinations were diverse within these eight trials and generally patient 7 numbers were low. 8
From the available evidence we cannot conclude that live vaccines are safe altogether in 9 immunosuppressed IMID, SOT and when administered within two years after BMT. However, despite 10 the limitations discussed above it is re-assuring that in the examined patient groups serious side 11 effects or infections by the attenuated vaccine strain were extremely scarce after primary 12 vaccinations and revaccinations with the examined vaccines (MMR, YFV, VV, HZV, oral typhoid fever, 13 oral polio, BCG, smallpox). 14 We believe that our research of the existing literature is of help to the interested specialist 15 confronted with the decision process on whether to vaccinate an immunosuppressed patient. More 16 evidence regarding the safety and immunogenicity of live vaccinations in IMID and SOT patients 17 under various immunosuppressive therapies as well as in patients less than two years after BMT is 18 urgently needed. Vaccination recommendations need to be adapted on a regular basis, as more 19 scientific data regarding vaccination safety and efficacy, new vaccines as well as new 20 immunosuppressive therapies will become available. 21
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